テキサス大学Health Science Center at San Antonio ポスドク募集

テキサス大学Health Science Center at San Antonioの同僚のPIがポスドクを募集しています。以下が募集広告になります。ご不明な点があれば、担当者へ直接お問い合わせください。

Postdoc Positions Focusing on Gene Regulation in Cancer Progression Multiple postdoctoral positions are available in the laboratory of Dr. Jason Liu (http://molecularmedicine.uthscsa.edu/FAC_Research.aspx?facID=206) in the Department of Molecular Medicine at the University of Texas Health Science Center at San Antonio (UTHSCSA). The focus of the lab is studying enhancer function and epigenetic mechanism in gene regulation in cancer progression. Selected candidates will perform highly interdisciplinary and collaborative scientific research in one or more of the following projects, working with human cell lines, mouse models and clinical samples:
(1) Explore the function of signaling-regulated enhancers in breast and prostate cancers, and understand how enhancers are regulated by the crosstalk of different signaling pathways including sex hormones, inflammation signals and metabolic signals;
(2) Decipher the epigenetic and chromatin 3D level changes in enhancers upon developmental/pathological stimuli or during hormone/drug resistance acquisition;
(3) Identify diagnostic/prognostic biomarkers and therapeutic targets for cancer and develop drugs for pre-clinical studies and potential clinical applications.
Our research integrates next-generation sequencing (NGS)-based technologies and bioinformatics tools to investigate the component, epigenetic, and 3D level changes of enhancers in cancers (refer to Cell, 2014 159: 358–373). We are efficiently combining biochemical, cellular, and animal model-related studies with different NGS-based assays. Our research program will help the trainees from both wet and dry lab sides to build up strong expertise and training record in molecular biology and multi-omics (genomics, transcriptomics, proteomics, epigenomics and metabolomics).
Positions require a Ph.D. degree (or equivalent) in biochemistry, cell biology, cancer biology, bioinformatics, or closely related biological sciences. The candidates need to have high motivation
and strong molecular biology background. Any prior experience in patient-derived xenograft (PDX) models, breast/prostate cancer, and computational analyses will be valued.
San Antonio is one of the fastest growing cities. The UTHSCSA is the largest university of health science in South Texas and one of four medical schools in the UT System. The affiliated Cancer Therapy & Research Center (CTRC) is one of the NCI-designated national cancer centers in the state of Texas. A competitive salary and benefits package will be provided.
To apply:
Please send the application package in one single pdf file including a cover letter briefly describing your previous experience and your future research interest/plan, curriculum vitae with list of publications, and contact information of at least three references to the following email. You are also welcome to send any inquiries or questions you might have.
Contact information:
Dr. Jason Liu
Department of Molecular Medicine
The University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX, 78229-3900
Email: LiuZ7@uthscsa.edu
Institution Web Site: http://molecularmedicine.uthscsa.edu/index.aspx
"All Postdoctoral appointments are designated as security sensitive positions."
"The University of Texas Health Science Center at San Antonio is an Equal Employment Opportunity/Affirmative Action Employer including protected veterans and persons with disabilities."



カルフォルニア州ロサンゼルス、Cedars-Sinai Medical Center研究員募集

カルフォルニア州ロサンゼルス、Cedars-Sinai Medical Center, Yamashita Labでは意欲のある研究員を2名募集しています。

1:糸球体腎炎の発病メカニズム、特にTLRとEGFRの半月体形成性糸球体腎炎における役割について、cell culture, animal model, そしてヒトの腎生検組織を用いて調べています。
また、これに加えて、mitochondrial injury, inflammasomes, trained immunityそしてACEのRAS非依存的な腎炎への影響についても調べています。
Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal. 2012 Jul 17; 5(233):ra50.
TRIF-independent branch of TLR3 signaling. J Immunol. 2012 Mar 15; 188(6):2825-33.
Antiviral innate immunity disturbs podocyte cell function. J Innate Immun. 2013; 5(3):231-41.
Renal tubular ACE-mediated tubular injury is the major contributor to microalbuminuria in early diabetic nephropathy. Am J Physiol Renal Physiol. 2017 Nov 29[Epub ahead of print]
非常にsupportiveな大ボスならびにCollaborator達(Drs. Moshe Arditi, Kenneth Bernstein, David Engman, Ravi Thadhani, and Ananth Karumanchi)に囲まれて、ラボを立ち上げました。非常に面白い数々のTransgenic miceや機材、試薬も揃っており、非常に恵まれた環境です。私達のグループには現在25人が働いており、私も含めて6人の日本人研究者が在籍しています。みなさん非常に協力的で環境の変化にも適応しやすいかと思います。

2. 豊富な腎生検のデータ(2006以降だけでも37,000件)や臨床データを用いて、臨床研究を行っています。全体の内、70%が自己腎(Native Kidney)で30%が移植腎(Transplant Kidney)です。Transplant Centerでは腎移植自体も活発に行われており、年間200例ほど行われています。これだけ大きなデータがあれば、腎生検/腎病理に関係することであれば、臨床上の些細な疑問も含めてすべてプロジェクトになり、比較的簡単に論文化(少なくとも年3-4本)されると思います。

Cedars-Sinai Medical Centerはビバリーヒルズにある、およそ900床の病院でそれに併設している研究所では活発にtranslational researchが行われております。ロサンゼルスは気候もよく、日本の食材も簡単に手に入り、また日本人も多いため、他の州に比べて非常に快適な生活が送れると思います。私が所属するRenal Pathologyは腎生検標本年間3600例を有し、私も含め5人のrenal pathologistsが所属するアメリカ西海岸最大の施設です。うち、移植腎生検も活発に行われており、年間700件以上あります。
また、2017年11月よりMGHのNephrologyのトップであったDr. Ravi ThadhaniとBeth Israel HospitalのDr. Ananth Karumanchi(両者ともHarvardのProfessor)がCedars-Sinaiに移ってきており、共同研究を行っています。腎臓研究はますます活発になっていくと思います。

給与:Cedars-Sinai Medical Centerの内規に沿ったものとなります。


Michifumi Yamashita, MD, PhD, FASN
Assistant Professor
Department of Pathology & Laboratory Medicine
Cedars-Sinai Medical Center
8700 Beverly Blvd. PACT 500
Los Angeles, CA 90048
Email: Michifumi.Yamashita@cshs.org



Boston University School of Medicine Postdoctral Position

A Postdoctoral Associate position is available immediately at Boston University School of Medicine in the laboratory of Dr. Huiping Zhang to study the genetic and epigenetic mechanisms of alcohol use disorders (AUD) and other mental disorders. The candidate will be mainly working on a NIH-funded project to (1) profile microRNA and mRNA transcriptome alterations in postmortem brains of alcoholic subjects using RNA-Seq, (2) construct microRNA-mRNA regulatory networks using bioinformatics programs, (3) validate AUD-associated microRNA and mRNA expression changes using human embryonic stem cell (hESC)-derived neurons as models, and (4) refine microRNA-mRNA regulatory networks using 3' UTR reporter assays. Further information about the research directions may be found at: http://www.bumc.bu.edu/genetics/huiping-zhang-ph-d/.
Experience in one or more of the following areas is desired: RNA-sequencing and bioinformatics, stem cell differentiation, reporter gene assays, and genome editing. Experience in stem cell differentiation and reporter gene assay is preferred. Strong written and oral communication skills are required.
Candidates should have a recent Ph.D. in genetics, cell biology, neuroscience, or a related discipline.
Boston University is located in Boston, Massachusetts. Boston University is an equal opportunity/affirmative action employer. NIH scale salary support is available.
To apply for this position, please email your CV, a cover letter detailing research experience, and contact information for three references to Dr. Huiping Zhang (huipingz@bu.edu).

Posted by Huiping Zhang(huipingz@bu.edu)


A Postdoctoral Position Available at Cleveland Clinic Lerner Research Institute in the USA

2018年3月発足予定のMatsuoka Labでは研究推進の主力となる熱意ある研究員を募集しています。臓器形成および再生時(とりわけ神経組織)の脈管形成機序の基本原理の解明を目指し、主にゼブラフィッシュをモデル動物として精力的に研究を進めていける意欲的な研究員の応募をお待ちしております。

A postdoctoral position is available in Ryota Matsuoka's Laboratory at the Lerner Research Institute, Cleveland Clinic. This newly established group starting in March, 2018, aims to define the cellular and molecular basis of vascular and lymphatic assembly in the central nervous system (CNS) using zebrafish and mouse as model organisms. Dr. Matsuoka's past work addressed how the vascularization of tissues surrounding the spinal cord is established in zebrafish (Matsuoka et al. eLife, 2016: PNAS, 2017) and how retinal neural circuits are organized in mouse (Matsuoka et al. Nature, 2011: Neuron, 2011). The future lab projects are directed towards understanding dynamic coordination of neuronal and vessel growth at the cellular and molecular level, which leads to the formation of the mature, functional CNS in vertebrates. The lab uses a combination of advanced 3D imaging, forward and reverse genetics to uncover this coordinated process during development and regeneration, with the goal to reconstitute vascularized functional neuronal tissues following CNS disease/injury.
The successful applicant is expected to apply for external fellowships, present data at scientific conferences, and prepare manuscripts for publication. Candidates with a publication record in developmental biology, genetics, neuroscience, or cell biology are preferred. Previous experiences working with animal models are also preferred.

Review of applicants will start immediately and continue until the position is filled. The stipend levels follow the current NIH scale, and start date is flexible. The contract will be renewed annually and extended for a period of 4 years and possibly longer, dependent upon satisfactory progress and the lab's funding situation. Interested individuals should submit a single PDF file containing the following materials to matsuoka.lab.recruit@gmail.com:
1) CV, including a list of publications and contact information for 2‐3 references
2) Cover letter describing previous research, research interests, and career goals

For more information, please contact at matsuoka.lab.recruit@gmail.com.
Ryota Matsuoka, Ph.D.
Principal Investigator
Lerner Research Institute, Cleveland Clinic
9500 Euclid Avenue
Cleveland, OH 44195, USA

投稿者:Ryota Matsuoka


Temple University School of Medicine ポスドク募集

私の所属するTemple University School of Medicine, Department of Physiology
(Philadelphia)で教授のRosario Scalia PhDがNIH RO1 grant 取得に伴い新たに
Postdoctoral Fellow を 募集致します。このgrantではmicrocirculationにおける血管炎症

Postdoctoral position
Department of Physiology
Temple University School of Medicine, Independence Blue Cross Cardiovascular
Research Center.
Project Title: The role of aging on vascular signal transduction and endothelial
inflammation in micro-circulation.
Position Type: Postdoctoral Position at an Academic Institution
My laboratory is looking for a post-doctoral fellow (commitment for 2 years or more) to
conduct collaborative in vitro and in vivo research experiments focused on the signal
transduction mechanisms of cardiovascular and adipose inflammation and aging.
Cutting-edge cell biological and biochemical approaches, genetic mouse models, large
animal models and human tissue specimens will be employed during the training period.
Applicants must have a Ph.D. or M.D. degree. One position is currently available with
full financial support (NIH standard) up to 4 years.

Preferred Qualifications:
1. Familiarity with at least one of the followings: molecular biology, organelle/cell
biology, biochemistry, mouse models, intravital microscopy, and surgical skills.
2. Publication record in biomedical journals.

Rosario Scalia, PhD
Professor of Medicine
Temple University School of Medicine
Department of Physiology
Independence Blue Cross Cardiovascular Research Center
3500 N. Broad Street
Philadelphia, PA 19140

イタリア系で陽気なScarlia先生のラボは比較的小さなラボですがNIH Grantの更新に伴
応募あるいは興味、質問のある方はCV (PDF)を添付して下記メールアドレスまで 気軽











〒241-8515 横浜市旭区中尾 2-3-2
神奈川県立がんセンター 臨床研究所 

〒241-8515 横浜市旭区中尾 2-3-2
TEL:045-520-2222(代表) 内線2105


笹田 哲朗
電話(045)520-2222(代表) 内線5063
e-mail: tsasada@kcch.jp


投稿者:笹田 哲朗(tsasada@kcch.jp)


Princess Margaret Cancer Centre, University of Toronto ポスドク募集

Princess Margaret Cancer Centre, University of Toronto の平野 直人 研究室では、ポスドク研究員を若干名募集します。研究内容は cancer immunotherapy in humans です。すべて研究はヒトレベルで行い、ヒト以外、例えばマウスでの実験は必要最小限にとどめます。Academia のみならず、industry との共同研究もさかんで、first-in-human の clinical trial を目指した basic, translational, and clinical research を行って頂きます。TIL や、engineered T cells を用いた adoptive T cell therapy clinical trials も行っています。

1. 安全かつ有効な CAR 及び TCR gene therapy の開発。
2. 新規 peptide/HLA multimer 技術を用いた抗原特異的 T 細胞の解析。
3. HLA 拘束性抗原プロセッシングと提示機構の解析。

1. Kagoya et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. (in press)
2. Ghazarian et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. 2017
3. Yamashita et al. HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway. Nat Commun. 2016
4. Kagoya et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016
5. Butler and Hirano. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev. 2014

応募資格:ヒトがん免疫療法に興味をお持ちの方、免疫学、分子生物学,生化学的手法を習得されている方、そして何よりも cure cancer を目指している方を求めます。

待遇:Princess Margaret Cancer Centre, University Health Network の規定に従います。4年。

応募書類:1. 履歴書と業績リスト(英語)、2. 推薦者 2-3名の連絡先、3. これまでの研究内容と、志望動機 (日本語可) を e-mail で naoto.hirano@uhnresearch.ca までお送りください。不明な点は、遠慮無くお問い合わせください。

平野 直人

Naoto Hirano, PhD, MD
Associate Director for Research
Tumor Immunotherapy Program
Senior Scientist
Princess Margaret Cancer Centre

Department of Immunology
University of Toronto

投稿者:平野 直人


Dana-Farber Cancer Institute研究員募集


Research positions available (computational biologist, bioinformatician, pathologist, anatomic pathologist, diagnostic pathologist, other experts can be considered)

I am seeking candidates for research positions (pathologist, computational biologist, and/or bioinformatician) in my laboratory at Dana-Farber Cancer Institute (DFCI), Brigham and Women's Hospital (BWH), the Broad Institute of MIT and Harvard, Harvard T.H. Chan School of Public Health, and Harvard Medical School, in Boston, MA, USA. Salary can be offered if a candidate has specific skills and expertise (such as Pathology, Computational Biology, and Bioinformatics). A position may be a bioinformatic analyst, postdoctoral fellow, or research scientist. A new lab member will be affiliated with Program in MPE Molecular Pathological Epidemiology at BWH. A new computational biologist/bioinformatician will also be affiliated with Broad Institute of MIT and Harvard. Candidates in other areas can be considered; other areas include epidemiology, biostatistics, molecular biology, immunology, microbiology, and clinical medicine. Candidates with funding support will be highly consi!
dered, but candidates without funding will also be considered.

My laboratory is The "Molecular Pathological Epidemiology" (MPE) Laboratory, which is a very unique, interdisciplinary multi-institutional laboratory. I have been selected to receive 7-year funding of the Outstanding Investigator Award (OIA) from NIH/NCI (2015-2022; http://grantome.com/grant/NIH/R35-CA197735-01). I established an integrative science of MPE (Ogino et al. J Natl Cancer Inst 2010; Ogino et al. Nat Rev Clin Oncol 2011; Field et al. JAMA 2013; etc), and have been making the history of MPE. I have been organizing the International MPE Meeting Series (www.mpemeeting.org). My MPE lab has been working on not only colorectal cancer, pancreatic cancer, and gastrointestinal neuroendocrine tumors, but also methods that can be used in many different areas. We have been working on “immuno-MPE”, “pharmaco-MPE”, “microbiology-MPE”, MPE method development, and integration of MPE and other areas such as causal inference, health co!
mmunication, and comparative effectiveness research. We have been utilizing resources of the Nurses' Health Study (following 121,700 women since 1976), the Health Professionals Follow-up Study (following 51,500 men since 1986), GECCO (Genetics and Epidemiology of Colorectal Cancer Consortium), Alliance trials, and other resources. For more information, please visit these links.

Please email me (shuji_ogino@dfci.harvard.edu) your CV or any inquiry. Please pass this information to anyone who may be interested. Please note that I may not reply to all inquiries.

Selected original and concept papers:

X Liao et al. NEJM 2012; R Nishihara et al. NEJM 2013; AT Chan et al. NEJM 2007; E Barry et al. Nature 2013; R Straussman et al. Nature 2012; M Giannakis et al. Nat Genet 2014; R Nishihara et al. JAMA 2013; T Morikawa et al. JAMA 2011; AT Chan et al. JAMA 2009; K Nosho et al. Gastroenterology 2009; K Nosho et al. J Pathol 2010; S Fink et al. Sci Transl Med 2014; ZR Qian et al. J Clin Oncol 2013; A Kostic et al. Genome Res 2012; M Song et al. JNCI 2015; K Inamura et al. JNCI 2014; P Lochhead et al. JNCI 2013; S Ogino et al. JNCI 2013; A Kuchiba et al. JNCI 2012; M Song et al. Gut 2016; M Yamauchi et al. Gut 2012; M Giannakis et al. Nat Genet 2014; K Mima et al. Cancer Immunol Res 2015; K Mima et al. JAMA Oncol 2015; K Inamura et al. JNCI 2016; K Mima et al. Gut 2016; M Song et al. JAMA Oncol 2016; M Giannakis et al. Cell Reports 2016; Y Cao et al. Gastroenterology 2016; R Mehta et al. JAMA Oncol 2017; T Hamada et al. J Clin Oncol 2017; R Mehta et al. Gastroenterology 2017; S !
Bullman et al. Science 2017.


ボストンにある私のThe Molecular Pathological Epidemiology (MPE) Laboratory分子病理疫学研究室で研究室員(computational biologist, bioinformatician, pathologist, anatomic pathologist, diagnostic pathologist あるいは他の分野)を募集しています。私のMPE研究室は中心はDana-Farber Cancer Instituteに位置しながらハーバード大学関連のいくつかの施設(Dana-Farber Cancer Institute, Brigham and Women's Hospital, the Broad Institute of MIT and Harvard, Harvard T.H. Chan School of Public Health, and Harvard Medical School)にまたがって存在し、機能しています(従来のラボの概念を超越しています)。私は日本人で現在唯一のNCI R35 Outstanding Investigator Award (OIA) Grant 保持者のようです(http://grantome.com/grant/NIH/R35-CA197735-01)。ポジションとしては常任研究員、ポスドクのいずれかが可能で、Program in MPE Molecular Pathological Epidemiology (Brigham and Women’s Hospital)にも属することになります。経験、能力(特にPathology, Co!
mputational biology/bioinformaticsの能力)に応じて、自前のグラントなしでも給与のサポートすることも可能です。自前のグラント(フェローシップ等)サポートがありますと、ポジションをオファーする可能性が高まります。Computational biologist/bioinformaticianの方はThe Broad Institute of MIT and Harvardにも所属して頂きます。その他、Epidemiology、Biostatistics、Molecular Biology、Immunology, Microbiology, 臨床医学のbackgroundを持つ方も考慮しており、得意な分野・経験を生かしていただきます。プロジェクトは大腸癌、膵臓癌、消化器内分泌腫瘍のMolecular Pathological Epidemiology (MPE、分子病理疫学)、Immuno-MPE(免疫分子病理疫学)、Pharmaco-MPE (薬理分子病理疫学)、 Microbiology-MPE(微生物分子病理疫学)、病気を限定しないMPE解析手法の開発、あるいはMPEと他の分野とのあらたな統合分野の設立と多岐にわたります。ラボメンバーのCareer Developmentのサポートも充実しています(このリンクをご覧ください http://uja-info.org/findingourway/post/1484/)。私の指導のもとで、人にもよりますが、2年間の研究留学で、筆頭著者でおよそ2-4本の高質の論文を出していますし、Co-First Authorship をとれることが多いです。これまでの2年間いたポスドクの最高記録は8本の筆頭著者論文です(Co-first author論文をいれると15本を超えるでしょうか)。

MPEは私が創造した学問分野で、その名が示すとおり、分子病理学と疫学の統合という新しい学問分野です(S Ogino et al. JNCI 2010; S Ogino et al. Nat Rev Clin Oncol 2011; A Field et al. JAMA 2013; etc)。私は2016年5月に第3回国際分子病理疫学学会を主催し、成功させ、すでに第4回国際分子病理疫学学会を2018年5月に計画中です(www.mpemeeting.org)。このように分子病理疫学の歴史を作っています。

私のラボでは大規模な前向き疫学コホートを使って大腸癌と膵臓癌の様々な分子異常の疫学的病因を研究しています。ハーバード大学公衆衛生大学院とBrigham and Women’s Hospitalではこれまで当初は健康な12万人の女性を40年(Nurses' Health Study、http://www.channing.harvard.edu/nhs/)、5万人の男性を30年(Health Professionals Follow-up Study、http://www.hsph.harvard.edu/hpfs/)追跡して、病気の発生を疫学的に研究してきました。他にも様々なコホート、トライアル(Alliance Trials)、コンソーシアム(GECCO)あるいはデータベースを駆使して研究を進めています。我々のMPE Researchの強みは最近のさまざまな論文で示されています(上に主要な論文を列挙しました)。分子病理疫学と私の研究室についてはこれらのサイトをご覧ください。

Shuji Ogino, MD, PhD, MS

Chief, Program in MPE Molecular Pathological Epidemiology at Brigham and Women’s Hospital

Professor of Pathology at Harvard Medical School, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute

Professor (Epidemiology) at Harvard T.H. Chan School of Public Health

Associate Member at Broad Institute of MIT and Harvard



Cincinnati Children’s, Chromatin Regulation, ポスドク募集

アメリカ Cincinnati Children’s Hospital, Iwafuchi Labでは、細胞分化を司るクロマチン制御機構の解明に挑むパイオニアを探しています。興味のある方は、下記のFlyerをご参照の上、お気軽にお問い合わせください(日本語と英語、どちらでも構いません)。

We are seeking a highly motivated and creative scientist for a postdoctoral position in the recently established laboratory of Makiko Iwafuchi-Doi at Cincinnati Children’s Hospital Medical Center, USA. We are keen to reveal chromatin regulatory principles underlying dramatic cell fate changing events that occur in embryonic development, tissue repair (physiological reprogramming), and diseases, and ultimately to utilize this knowledge to precisely engineer cell fates. We currently focus on how different families of pioneer transcription factors establish cell-type-specific chromatin landscape. We are building a team to tackle these questions, combining developmental biology and human stem cells and organoid culture systems with genetics and genomics/bioinformatics.

The ideal candidate will have at least one first author publication and a strong background in cell/developmental biology and molecular biology. Prior experience in bioinformatics is preferred but not a prerequisite. Successful and motivated candidates wishing to switch from other fields will also be considered.

The Iwafuchi lab is the member of Division of Developmental Biology and Center for Stem Cell & Organoid Medicine (CuSTOM), a highly collaborative and interactive institution with Pluripotent Stem Cell, Genome Editing, and Imaging core facilities. Postdoctoral fellows are supported by the Office of Postdoctoral Affairs and the Office of Career Development.

If you are interested in joining the lab, please send your CV including the names of 3 references, along with a brief statement of your research interests to Maki (Makiko.Doi@cchmc.org). We look forward to hearing from you!

Cincinnati Children’s Hospital Medical Center is an Affirmative Action/ Equal Opportunity Institution.

Makiko Iwafuchi-Doi, PhD
Assistant Professor
Division of Developmental Biology
Center for Stem Cell & Organoid Medicine
Cincinnati Children’s Hospital Medical Center
Phone: +1-513-636-0882
Email: Makiko.Doi@cchmc.org

投稿者:Makiko Iwafuchi-Doi(Makiko.Doi@cchmc.org)





助成金総額 1,500万円/年

 内訳・助成対象者の生活費相当額 約700万円
   ・助成対象者の研究費    約350万円
   ・育成支援教員の研究費    300万円
   ・所属機関の管理費      150万円





 lotte_zaidan@lotte.co.jp (研究助成事業担当)

投稿者:小松 宏


  • 2018年01月
  • 2017年12月
  • 2017年11月
  • 過去ログ一覧